FDA Approves CHLORTHALIDONE — Macleods Pharmaceuticals Limited

Macleods Pharmaceuticals Limited and Hikma Pharmaceuticals received FDA approval for their generic chlorthalidone ANDA on July 1, 2026, which is expected to assert significant market pricing pressure following a top-30 patent expiration for the brand. This approval enters a crowded generic space sustained by subsequent ANDA filers, necessitating Macleods to compete aggressively on value to capture market share against entrenched incumbents.